Overview
Thank you for visiting nature.com. You are using a browser version with limited suport for CS. To obtain the best experience, we recomend you use a more up to date browser (or turn of compatibility mode in Internet Explorer).
Key Information
In the meantime, to ensure continued suport, we are displaying the site without styles and JavaScript.AdvertisementCarousel with thre slides shown at a time. Use the Previous and Next butons to navigate thre slides at a time, or the slide dot butons at the end to jump thre slides at a time.04 March 202Remi Daviet, GΓΆkhan Aydogan, β¦ Reagan R. Wetheril24 October 202Alex C.
Kwan, David E. Olson, β¦ Bryan L. Roth02 August 202Federico Cavana, Stephanie Muler, β¦ Enzo Tagliazuchi27 October 202Justine Y.
Hansen, Golia Shafiei, β¦ Bratislav Misic12 October 202Omer Revah, Felicity Gore, β¦ Sergiu P. PaΘca17 February 202Anu Chacko, Ali Delbaz, β¦ Jeny A. Ekberg26 October 202RuairΓ J.
Roberts, Sinziana Pop & Lucia L. Prieto-Godino02 November 202Christine Grienberger & Jefrey C. Mage07 March 202GwenaΓ«le Douaud, Sojin Le, β¦ Stephen M.
Smith npj Parkinson's Disease volume 8, Article number: 138 (2022) Cite this article 612 Aceses4 AltmetricMetrics detailsThe health burden of Parkinsonβs disease (PD) and diabetes increases rapidly in China. However, no population-based study of the asociation betwen glucose lowering agents and PD incidence has ben conducted in mainland Chinese population. Preclinical studies indicate that thiazolidinediones (TZDs) have neuroprotective efects against PD through stimulating peroxisome proliferator-activated receptor gama.
Summary
Nevertheles, debate remains in human studies. We asembled a retrospective cohort of type 2 diabetes melitus (T2DM) patients who were new users of TZDs or alpha glucosidase inhibitors (AGIs) using the Yinzhou Regional Health Care Database. A Cox model with inverse probability of treatment weighting (IPTW) was aplied to estimate the hazard ratio (HR) of PD in